PROTIA INC. Logo

PROTIA INC.

Develops and manufactures in-vitro diagnostic kits and instruments.

303360 | KO

Overview

Corporate Details

ISIN(s):
KR7303360002
LEI:
Country:
South Korea
Address:
서울특별시 강서구 양천로 401, 강서한강자이타워 A동 702호, 강서구

Description

PROTIA INC. is an in-vitro diagnostics (IVD) company that develops, manufactures, and sells a wide range of diagnostic kits and instruments. The company is particularly known for its flagship product, PROTIA Allergy-Q, a multiplex allergy diagnostic kit for the quantitative determination of allergen-specific IgE. Its portfolio also includes point-of-care testing (POCT) solutions like the ImmuneCheck IgG kit, diagnostic tests for infectious and autoimmune diseases, cancer, and antibiotic susceptibility, as well as the ANITIA line for companion animal allergy testing. In addition to its product offerings, PROTIA provides comprehensive protein analysis services, including LC-MS/MS and characterization analysis, aiming to contribute to early disease prediction and diagnosis through innovative technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-05-21 00:00
증권발행결과(자율공시)
Korean 5.4 KB
2019-05-15 00:00
주주총회소집공고
Korean 180.0 KB
2019-05-13 00:00
주요사항보고서(유상증자결정)
Korean 31.1 KB
2019-05-10 00:00
기타주요경영사항(자율공시)
Korean 6.0 KB
2019-04-25 00:00
기업설명회(IR)개최결과
Korean 7.1 KB
2019-04-18 00:00
주주총회소집결의
Korean 12.5 KB
2019-04-18 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2019-04-16 00:00
기업설명회(IR)개최
Korean 7.4 KB
2019-04-04 00:00
기타주요경영사항(자율공시)
Korean 5.5 KB
2019-03-28 00:00
사업보고서 (2018.12)
Korean 845.8 KB
2019-03-25 00:00
주식매수선택권부여에관한신고
Korean 13.4 KB
2019-03-25 00:00
정기주주총회결과
Korean 21.2 KB
2019-03-20 00:00
기업설명회(IR)개최결과
Korean 6.8 KB
2019-03-14 00:00
감사보고서제출
Korean 10.4 KB
2019-03-13 00:00
기업설명회(IR)개최
Korean 7.4 KB

Automate Your Workflow. Get a real-time feed of all PROTIA INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PROTIA INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PROTIA INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.